Erratum

Source: Letters in Drug Design & Discovery, Volume 3, Number 5, July 2006 , pp. 356-356(1)

Publisher: Bentham Science Publishers

Buy & download fulltext article:

Price: $63.10 plus tax (Refund Policy)

Abstract:

In the article entitled "Pyrazinobenzodiazepines as Potent Nonpeptide Vasopressin Receptor Antagonists" by Jay M. Matthews et al. (Letters in Drug Design & Discovery, 2005, Vol. 2(3), 219-223) the authors report that for the Page 222, column 1, paragraph 3, line 9: The reduction of urine osmolality should be 77% (not 23%). Page 222, column 2, line 3: The alteration of urine osmolality should be -81% (not -19%).

Document Type: Research article

DOI: http://dx.doi.org/10.2174/157018006777574186

Publication date: 2006-07-01

More about this publication?

Letters in Drug Design & Discovery publishes original letters on all areas of rational drug design and discovery including medicinal chemistry, in-silico drug design, combinatorial chemistry, high-throughput screening, drug targets, and structure-activity relationships. The emphasis will be on publishing quality papers very rapidly. Letters will be processed rapidly by taking full advantage of Internet technology for both the submission and review of manuscripts. The journal is essential reading to all pharmaceutical scientists involved in research in drug design and discovery.